Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models
PI3K pathway activation is frequently observed in triple negative breast cancer (TNBC). However, single agent PI3K inhibitors have shown limited anti-tumor activity. To investigate biomarkers of response and resistance mechanisms, we tested 17 TNBC patient-derived xenograft (PDX) models representing...
Main Authors: | Zhanfang Guo, Tina Primeau, Jingqin Luo, Cynthia Zhang, Hua Sun, Jeremy Hoog, Feng Gao, Shixia Huang, Dean P. Edwards, Sherri R. Davies, Rebecca Aft, Li Ding, Matthew J. Ellis, Shunqiang Li, Cynthia X. Ma |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/12/3857 |
Similar Items
-
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
by: Ana C. Garrido-Castro, et al.
Published: (2020-11-01) -
Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy
by: Xin Peng, et al.
Published: (2021-11-01) -
Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy
by: Achira Roy, et al.
Published: (2015-12-01) -
Orthotopic Patient-Derived Xenografts of Gastric Cancer to Decipher Drugs Effects on Cancer Stem Cells and Metastatic Dissemination
by: Julie Giraud, et al.
Published: (2019-04-01) -
Positive Effects of PI3K/Akt Signaling Inhibition on PTEN and P53 in Prevention of Acute Lymphoblastic Leukemia Tumor Cells
by: Elahe Naderali, et al.
Published: (2019-08-01)